Go Pro
NASDAQ:ACIU

AC Immune Q2 2026 Earnings Report

AC Immune logo
$2.83 +0.10 (+3.66%)
Closing price 04:00 PM Eastern
Extended Trading
$2.83 0.00 (0.00%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AC Immune EPS Results

Actual EPS
$0.03
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

AC Immune Revenue Results

Actual Revenue
$18.67 million
Expected Revenue
$9.59 million
Beat/Miss
Beat by +$9.07 million
YoY Revenue Growth
N/A

AC Immune Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
12:30PM ET

Upcoming Earnings

AC Immune's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

AC Immune Earnings Headlines

CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
See More AC Immune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email.

About AC Immune

AC Immune (NASDAQ:ACIU) SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them. Its pipeline has included vaccine and antibody-based approaches aimed at amyloid-beta and tau, as well as programs addressing other proteins linked to neurodegeneration. The company has also pursued collaborations with larger pharmaceutical companies to advance selected candidates.

AC Immune serves the global biopharmaceutical and healthcare markets through research and development conducted primarily in Switzerland and through international partnerships and clinical studies. Andrea Pfeifer has served as the company’s chief executive officer and has been associated with its leadership since its early development.

View AC Immune Profile